Výsledky vyhledávání - "Mia Thagesson"

Akademický článek

Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)

Background Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen pr

Externí odkaz: https://doaj.org/article/3ded16f9cf504c5983b33e362b58d5fd

Zobrazit plný text záznamu

Akademický článek

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Autor: Anne Månsson Kvarnhammar, Niina Veitonmäki, Karin Hägerbrand, Anna Dahlman, Karin Enell Smith, Sara Fritzell, Laura von Schantz, Mia Thagesson, Doreen Werchau, Kristine Smedenfors, Maria Johansson, Anna Rosén, Ida Åberg, Magnus Winnerstam, Eva Nyblom, Karin Barchan, Christina Furebring, Per Norlén, Peter Ellmark

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)

Abstract Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in

Externí odkaz: https://doaj.org/article/ac146a36143540ed83d59ae4ac9773f4

Zobrazit plný text záznamu

The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo

Autor: Peter Ellmark, Adnan Deronic, Mia Thagesson, Karin Enell Smith, Doreen Werchau, Anneli Nilsson

Publikováno v: Cancer Immunology, Immunotherapy

Non-responders to checkpoint inhibitors generally have low tumor T cell infiltration and could benefit from immunotherapy that activates dendritic cells, with priming of tumor-reactive T cells as a result. Such therapies may be augmented by providing

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72cbad71c14c89fdc4d61bb02bd93ac6
http://europepmc.org/articles/PMC8571159

Zobrazit plný text záznamu

Abstract 4155: Mitazalimab, a potent CD40 agonist in combination with chemotherapy redirects and activates tumor infiltrating myeloid cells

Autor: Karin Enell Smith, Mia Thagesson, Anneli Nilsson, Doreen Werchau, Peter Ellmark

Publikováno v: Cancer Research. 82:4155-4155

Mitazalimab is a human CD40 agonistic antibody developed for immunotherapy of cancer. Activation of CD40, expressed on myeloid cells, such as dendritic cells and tumor infiltrating macrophages, leads to improved T cell priming and initiation of T cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::02755ee721b25c79005540e381447edf
https://doi.org/10.1158/1538-7445.am2022-4155

Zobrazit plný text záznamu

751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb

Autor: Barnabas Nyesiga, Mia Thagesson, Anna Rosén, Karin Hägerbrand, Mattias Levin, Karin Barchan, Laura Varas, Anette Sundstedt, Anna Säll, Doreen Werchau, Peter Ellmark, Lill Ljung, Laura Von Schantz, Eva Lindqvist, Adnan Deronic

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)

BackgroundAlligator's Neo-X-Prime platform aims to enable antigen presenting cells to efficiently enhance priming of tumor neoantigen-specific T cells with the goal of overcoming PD-1 resistance in certain tumor types. We hypothesize that binding of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::254b3a98cca7dddc470b999478d652d6
https://doaj.org/article/9e6a3658910c424b887736939f0b115c

Zobrazit plný text záznamu

Abstract 1593: Mitazalimab, a potent CD40 agonist with potential for combination with chemotherapy

Autor: Mia Thagesson, Anette Fält, Karin Enell Smith, Charlotte Fält, Adnan Deronic, Peter Ellmark, Anneli Nilsson

Publikováno v: Cancer Research. 81:1593-1593

Mitazalimab (ADC-1013, JNJ-64457107) is a human CD40 agonistic antibody developed for immunotherapy of cancer. Activation of CD40, expressed on antigen-presenting cells (APC), leads to improved T cell priming and initiation of T cell-dependent anti-t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b47f2c9bafc70cc9ac1c7d002da03442
https://doi.org/10.1158/1538-7445.am2021-1593

Zobrazit plný text záznamu

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Autor: Sara Fritzell, Anne Månsson Kvarnhammar, Karin Enell Smith, Laura Von Schantz, Mia Thagesson, Doreen Werchau, Anna Rosén, Per Norlén, Karin Hägerbrand, Eva Nyblom, Peter Ellmark, Niina Veitonmäki, Christina Furebring, Kristine Smedenfors, Maria Johansson, Karin Barchan, Magnus Winnerstam, Ida Åberg, Anna Dahlman

Publikováno v: Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-14 (2019)

Background The CTLA-4 blocking antibody ipilimumab has demonstrated substantial and durable effects in patients with melanoma. While CTLA-4 therapy, both as monotherapy and in combination with PD-1 targeting therapies, has great potential in many ind

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09cbba20b753513ce8ee3f014583fcfc
http://europepmc.org/articles/PMC6458634

Zobrazit plný text záznamu

Abstract 3623: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

Autor: Per Norlén, Karin Hägerbrand, Anne Månsson-Kvarnhammar, Mia Thagesson, Kristine Smedenfors, Niina Veitonmäki, Anna Rosén, Peter Ellmark, Christina Furebring, Doreen Werchau, Maria C Johansson

Publikováno v: Cancer Research. 78:3623-3623

ATOR-1015 is a CTLA-4 x OX40 bispecific immune activating antibody developed for tumor-directed immunotherapy. ATOR-1015 binds both targets simultaneously, promoting cell-cell interactions expected to enhance the immuno-stimulating effect of the comp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::99798d935a49ff9eacda71fb81568f30
https://doi.org/10.1158/1538-7445.am2018-3623

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání